Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aligos Therapeutics Inc (ALGS)

Aligos Therapeutics Inc (ALGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Aligos Therapeutics Inc ONE CORPORATE DR. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 USA

www.aligos.com Employees: 82 P: 800-466-6059

Sector:

Medical

Description:

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is focused on the development of antiviral therapies for chronic hepatitis B and coronaviruses as well as liver diseases. Aligos Therapeutics, Inc. is based in SAN FRANCISCO, Calif.

Key Statistics

Overview:

Market Capitalization, $K 41,211
Enterprise Value, $K 22,801
Shares Outstanding, K 6,188
Float, K 5,891
% Float 95.20%
Short Interest, K 295
Short Float 4.76%
Days to Cover 6.45
Short Volume Ratio 0.39
% of Insider Shareholders 4.80%
% of Institutional Shareholders 60.43%

Financials:

Annual Sales, $ 2,190 K
Annual Net Income, $ -24,190 K
Last Quarter Sales, $ 170 K
Last Quarter Net Income, $ -19,880 K
EBIT, $ -87,980 K
EBITDA, $ -89,240 K

Growth:

1-Year Return -27.63%
3-Year Return -69.52%
5-Year Return -98.79%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 99.10%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.91 on 03/05/26
Next Earnings Date 05/05/26
Earnings Per Share ttm -8.59
EPS Growth vs. Prev Qtr 37.17%
EPS Growth vs. Prev Year 43.99%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-25 on 08/19/24

ALGS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -28.16%
Return-on-Assets % -20.01%
Profit Margin % -1,104.57%
Debt/Equity 0.00
Price/Sales 19.93
Price/Cash Flow N/A
Price/Book 0.81
Book Value/Share 8.67
Interest Coverage -0.15
60-Month Beta 2.67
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.